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Abstract
Auditory dysfunction under complex, dynamic listening conditions is a clinical
hallmark of Alzheimer’s disease (AD) but challenging to measure and manage.
Here, we assessed understanding of sinewave speech (a paradigm of degraded
speech perception) and general cognitive abilities in 17 AD patients, before and
following a 10 mg dose of donepezil. Relative to healthy older individuals,
patients had impaired sinewave speech comprehension that was selectively ame-
liorated by donepezil. Our findings demonstrate impaired perception of
degraded speech in AD but retained perceptual learning capacity that can be
harnessed by acetylcholinesterase inhibition, with implications for designing
communication interventions and acoustic environments in dementia.
Introduction
Alzheimer’s disease (AD) is associated with impaired
higher cortical auditory function and communication,
particularly in complex, dynamic acoustic environments,
and the role of hearing impairment in cognitive decline is
currently the focus of intense interest.1 Patients with AD
frequently struggle to understand spoken information in
the presence of background noise or when delivered in
unfamiliar accents or voices,2–4 restricting communication
and quality of life. Auditory dysfunction has been
identified as a harbinger of incipient dementia in AD.5
The role of acetylcholine in auditory function is highly
pertinent, particularly for dynamic perception under diffi-
cult or changing listening conditions or where there is a
requirement for auditory plasticity.6 Cholinergic system
degeneration is core to the disease process in AD and the
most widely used symptomatic therapies (the acetyl-
cholinesterase inhibitors) promote the effects of endoge-
nous acetylcholine.7,8 Cholinergic modulation impacts
early auditory processing in healthy older people.9 How-
ever, currently, there is little information about the effects
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of cholinergic modulation on auditory function and com-
munication in AD. Modulation of cholinergic transmis-
sion in AD has been shown to boost both verbal memory
and auditory cortical function.10 Speech perception is
therefore an attractive target for acetylcholinesterase inhi-
bition in AD; indeed, procholinergic verbal memory ben-
efit may depend in part on enhanced sensory encoding of
speech.
Here, we assessed degraded auditory perception and
the effect of increasing acetylcholinesterase inhibition in
patients with AD versus untreated healthy older people,
using the classical paradigm of sinewave speech.11 Sine-
wave transformation reduces speech signals to a series of
‘whistles’ (corresponding to formant contours) from
which spectral detail has been stripped. Normal na€ıve lis-
teners rapidly and spontaneously learn to understand
sinewave messages.12 We hypothesized that compared
with untreated healthy controls, AD patients in a relative
cholinergic deficiency state (prior to the next dose of
acetylcholinesterase inhibitor) would show impaired
understanding of sinewave speech but that this would
improve disproportionately to other cognitive functions
following a dose of acetylcholinesterase inhibitor, given
that sinewave speech perception is likely to depend on
cognitive plasticity and dynamic neural processing.
Methods
Participants
Seventeen patients with typical amnestic AD (eight
female; mean age 71.8 years) and 17 healthy older indi-
viduals (six female; mean age 66.6 years) participated. All
patients fulfilled consensus criteria for AD13 of mild to
moderate severity and all were established on Donepezil
10 mg/day when studied. No participant had a clinical
history of hearing impairment and participants abstained
from caffeinated beverages during the study. Demo-
graphic and clinical data for all participants are summa-
rized in Table 1. All participants gave informed consent
to participate in the study. Ethical approval was granted
by the London-Bromley Research Ethics Committee, in
accordance with Declaration of Helsinki guidelines.
Experimental procedures
Stimuli for the degraded speech experiment comprised
spoken three-digit numbers (of the form, ‘eight hundred
and ninety-seven’), converted after recording to sinewave
replicas using standard methods and delivered via head-
phones (see Fig. 1).
Each participant was assessed in the morning (baseline
session) and again the same afternoon (repeat session;
mean intersession interval 4.8 h; see Table 1). AD patients
began the baseline testing session at least 12 h following
their last dose of donepezil and then took their daily
10 mg dose of donepezil between sessions (mean
2.6  0.7 h prior to the repeat session). At each session,
all participants completed the test assessing sinewave
speech perception, a control test assessing perception of
clear (natural) speech and a standard general assessment
of cognitive functions (Table 1). The sinewave speech test
comprised 20 trials; two different three-digit number lists
were used for the baseline and repeat sessions and the
order of these lists was counterbalanced across partici-
pants. The clear speech test comprised 10 trials based on
a separate three-digit number list. In both tests, the task
on each trial was to transcribe the three-digit number
presented as fully as possible and each trial was scored as
correct or incorrect. For each participant at each test ses-
sion, we calculated a within-session change score (total
score on the second 10 trials minus total score on the
first 10 trials): this provided an index of intrinsic percep-
tual learning (i.e., improved perceptual responsiveness
resulting from sensory experience14), independent of
intervening acetylcholinesterase inhibition.
Data analyses
All data were analyzed using Stata14.0. Participant
groups were compared on demographic and baseline neu-
ropsychological data using two-tailed t-tests for continu-
ous variables and chi-square tests for categorical variables.
Neuropsychological performance was compared between
baseline and repeat sessions by calculating an intersession
change (difference) score for each test in each participant.
Change scores (both within-session and between sessions)
were entered as dependent variables in a series of two-
tailed independent sample t-tests for assessing between-
group differences and two-tailed one-sample t-tests for
within-group differences. Correlations between perceptual
performance and general clinical indices in the AD group
were assessed using Pearson’s correlation. General psycho-
metric data for participant groups were assessed at statisti-
cal significance threshold P < 0.01 (Bonferroni-adjusted
for multiple comparisons); key sinewave speech compar-
isons motivated by our specific prior hypothesis were
assessed at P < 0.05. Where normality assumptions were
violated we substituted nonparametric analogues of stan-
dard statistics (Wilcoxon rank-sum for independent sam-
ple t-tests, Wilcoxon signed-rank for one-sample t-tests).
Results
Participant group profiles and comparisons between
groups are presented in Table 1 and Figure 2. Participant
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groups were well-matched for age, gender, and other
demographic characteristics, and patient groups showed
the anticipated profiles of impairment on baseline general
neuropsychological assessment. For the healthy control
group and AD group considered separately, performance
on a range of general neuropsychological functions did
not alter significantly between baseline and repeat testing
sessions (z range = 0.042–1.92, all P > 0.01); there was no
significant effect of diagnosis on change in performance
between sessions.
For both the healthy control group and the AD group,
performance on perception of clear speech was essentially
at ceiling across test sessions for all participants. Both
groups showed perceptual learning of sinewave speech
across the baseline test session (AD: t16 = 3.92, P < 0.001;
controls: t16 = 5.66, P < 0.001); this intrinsic learning
Table 1. General and behavioral test performance characteristics in the participant groups.
Characteristic Session Healthy controls AD
Group comparison
Statistic P-value
General
Gender (M:F) NA 11:6 9:8 v2 = 0.49 0.486
Age (years) NA 66.6 (7.3) 71.8 (8.2) t = 1.93 0.062
Handedness (R:L) NA 16:1 17:0 NA NA
Education (years) NA 16.5 (1.8) 15.6 (2.6) t = 1.13 0.267
MMSE (/30) NA 29.9 (0.2) 23.9 (3.3) z = 4.99 <0.001
Symptom duration (years) NA NA 4.5 (2.7) NA NA
Donepezil duration (months) NA NA 20.8 (13.1) NA NA
Antidepressant therapy (no.)1 NA 2 2 NA NA
Behavioral tests
General cognitive
RMT Faces (/25): baseline 24.4 (0.9) 19.7 (3.6)2 z = 3.61 <0.001
change 0.3 (1.0) 0.0 (3.3) z = 0.89 0.375
RMT Words (/25) baseline 24.4 (1.5) 18.0 (3.4)2 z = 4.55 <0.001
change 0.1 (0.8) 0.4 (3.1) z = 0.77 0.443
GNT (/30) baseline 25.5 (3.6) 14.1 (8.3) z = 4.18 <0.001
change 0.8 (1.5) 0.6 (2.5) z = 1.81 0.071
WASI matrices (/32) baseline 25.5 (4.0) 11.6 (6.8) z = 4.42 <0.001
change 1.2 (2.7) 0.6 (3.4) z = 1.40 0.163
BPVS (/51) baseline 49.1 (1.7) 40.4 (10.1)2 z = 4.00 <0.001
change 0.5 (1.2) 0.6 (2.3) z = 2.09 0.038
Sinewave speech experiment
Sinewave speech (/20) baseline 15.4 (2.5) 10.3 (5.1) z = 3.40 <0.001
repeat 16.3 (2.7) 13.9 (3.7) z = 1.82 0.069
change 0.9 (3.1) 3.6 (3.7)3 t = 2.36 0.025
Session change score4 baseline 2.0 (1.5) 2.7 (2.8) t = 0.91 0.369
repeat 2.4 (2.1) 2.5 (1.4) t = 0.19 0.849
change 0.4 (2.2) 0.2 (3.3) t = 0.61 0.544
Clear speech control (/10) baseline 10.0 (0.0) 9.9 (0.2) NA NA
repeat 10.0 (0.0) 10.0 (0.0) NA NA
The Table shows mean (standard deviation) general demographic, clinical, and behavioral test data in the healthy control group and Alzheimer’s
disease (AD) patient group; comparisons between groups are also indicated. All AD patients were established on a standard daily 10 mg dose of
donepezil at the time of participation; the baseline session was conducted prior to their next, intersession dose of donepezil. The interval between
test sessions was similar for each group (healthy controls, 4.8  0.4 h; AD, 4.9  0.4 h; t32 = 0.85, P = 0.400). The right-hand columns show
the effect of statistical comparisons between participant groups for each test. Maximum scores for standard tests of neuropsychological functions
and for tests in the speech experiment (spoken numbers presented in sinewave form and in clear) are indicated in parentheses (see text and Fig. 1
for details). AD, Alzheimer’s disease; BPVS, British Picture Vocabulary Scale (Dunn & Whetton, 1982); F, female; GNT, Graded Naming Test
(McKenna & Warrington, 1980); L, left; M, male; MMSE, Mini-Mental State Examination score; NA, not applicable; R, right; RMT, Recognition
Memory Test (Warrington, 1984); WASI, Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999).
1no participant was taking memantine or other psychoactive agents;
2one AD patient did not complete the test due to lack of time;
3significant between-session performance difference within group (P < 0.001);
4index of intrinsic perceptual learning of sinewave speech (score on second 10 trials minus score on first 10 trials, within that session; see text
and Figure 2).
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effect did not differ significantly between groups
(t16 = 0.91, P = 0.369). However, the AD group was
significantly less accurate than the healthy control group
on perception of sinewave speech at baseline (z = 3.40,
P < 0.001) and showed a significant improvement
between sessions (i.e., following administration of done-
pezil; t16 = 4.01, P < 0.001) that was not evident in the
healthy control group (t16 = 1.19, P = 0.126). This differ-
ential improvement was reflected in a significant effect of
diagnosis on change in performance (t16 = 2.36,
P = 0.025 and evident in 13/17 (76%) of patients in the
AD group. Across the repeat test session, both groups
again showed comparable perceptual learning of sinewave
speech (AD: t16 = 7.35, P < 0.001; controls t16 = 4.75,
P < 0.001; group comparison t16 = 0.19, P = 0.849).
The effect of improved sinewave speech perception in
the AD group did not correlate with disease severity
(Mini-Mental State Examination score; r = 0.02,
P = 0.931), symptom duration (r = 0.23, P = 0.378) or
duration of donepezil treatment (r = 0.04, P = 0.889).
Across the participant cohort, there were no significant
performance differences between the two word lists used
in the sinewave speech test (Wilcoxon signed-rank:
z = 1.61, P = 0.108).
Discussion
We have shown that (relative to healthy older individuals)
patients with AD have impaired perception of degraded
(sinewave) speech and that this deficit is ameliorated by
acetylcholinesterase inhibition, under clinically relevant
dosing conditions. This procholinergic benefit in the AD
group did not extend to other cognitive measures over a
similar time-frame and did not correlate with general
indices of overall disease severity, arguing for a relatively
specific effect on degraded speech perception rather than
a generic enhancement of cognitive function or practice
effect. Patients with AD showed rates of improvement in
understanding sinewave speech comparable to healthy
controls both pre- and post-administration of donepezil,
suggesting that the intersession benefit was attributable to
the drug.
Figure 1. The spectrograms show examples of the stimuli used to
assess sinewave speech processing. A: natural (i.e., clear) three-digit
spoken number (‘eight hundred and eighty-seven’). B: the
corresponding sinewave replica. Frequency is depicted on the y-axis,
in kilohertz (kHz) and time is depicted on the x-axis, in milliseconds
(msec); the sinewave replica retains the centre frequencies of the
formant contours but omits the spectral detail evident in natural
speech. Numbers were spoken in quiet by a young adult male
speaker in a standard Southern English accent, and recorded as digital
wavefiles (sampling rate 44.1 kHz, mean (SD) duration 1485 (111)
msec) using Audacity software; sinewave stimuli were generated
from the natural speech recordings using a procedure under Praat
software (http://www.lifesci.sussex.ac.uk/home/Chris_Darwin/Praatsc
ripts/SWS) and root-mean-square intensity was fixed for all stimuli.
During testing, all stimuli were administered in a quiet room via ATH-
M50X Audio-Technica headphones, at a comfortable listening level
(at least 70dB) for each participant. Participants were instructed that
on each trial they would hear a distorted three-digit number and
asked to write down the number as fully as possible.
Figure 2. Profiles of sinewave speech comprehension by the
participant groups are shown for baseline and repeat behavioral test
sessions (see also Table 1). A: Alzheimer’s disease; B: Healthy
controls. For each group and test session, dark gray oblongs code
interquartile range and whiskers the overall range of scores for the
first 10 trials; light gray oblongs code interquartile range and whiskers
the overall range of scores for the second 10 trials; solid lines indicate
the mean change in scores between trial blocks in each test session;
and dotted lines indicate comparisons between sessions. Values falling
outside these ranges are indicated. aSignificant between-group
difference (P < 0.05); bsignificant within-group change (P < 0.05).
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Taken together our findings suggest that, in AD, choli-
nesterase inhibition acts to amplify the accuracy of sine-
wave speech perception, whereas intrinsic capacity for
perceptual learning of this degraded speech stimulus is
retained. These findings are in line with other work
demonstrating cholinergic effects on visual perception
and cortical function in AD,8 with retained endogenous
perceptual learning mechanisms.15 While the mechanism
of the procholinergic effect on degraded speech percep-
tion remains undefined, there are several plausible candi-
dates, acting alone or in concert: these include enhanced
precision of synaptic transmission and predictive filtering
in ascending auditory pathways and facilitation of spectral
integration, feature encoding and tracking in auditory
cortex.6,16–20
Sinewave speech provides a quantifiable metric for
speech perception under challenging listening conditions;
our findings are potentially relevant to a variety of daily
life situations (for example, accented speech, noisy tele-
phone lines, and cocktail party scenarios) that stress
speech perception mechanisms and present particular dif-
ficulties for patients with AD.1–4 The relative selectivity
of the present effect suggests that the pairing of pro-
cholinergic therapy with specific, dynamic auditory stim-
uli such as degraded speech may be required to train
and to measure perceptual benefit. Our findings have
clear implications for assessing dynamic perceptual
reserve, improving communication and designing inter-
ventions and acoustic environments from the early stages
of AD.5 Besides corroboration in larger cohorts using a
placebo-controlled design and drug-naive patients, future
work should address the pharmacological, neurophysio-
logical and neuroanatomical correlates of these findings
in relation to peripheral hearing, the circadian alertness
cycle and other disease factors and the durability and
translatability of sinewave speech effects to other adverse
listening paradigms.
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